Ubs Asset Management Americas Inc Rhythm Pharmaceuticals, Inc. Transaction History

Ubs Asset Management Americas Inc

$446 Billion
Q3 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 437,472 shares of RYTM stock, worth $43.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

437,472

Previous 227,627 92.19%

Holding current value

$43.5 Million

Previous $14.4 Million 207.17%

% of portfolio

0.01%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$65.14 - $104.57 $13.7 Million - $21.9 Million	209,845 Added 92.19%	437,472 $44.2 Million
Q2 2025 Aug 14, 2025	BUY	$46.95 - $68.11 $4.78 Million - $6.94 Million	101,845 Added 80.97%	227,627 $14.4 Million
Q1 2025 May 19, 2025	SELL	$48.56 - $61.02 $4.5 Million - $5.66 Million	-92,762 Reduced 42.45%	125,782 $6.66 Million
Q4 2024 Feb 14, 2025	SELL	$46.91 - $67.33 $320,348 - $459,796	-6,829 Reduced 3.03%	218,544 $12.2 Million
Q3 2024 Nov 14, 2024	SELL	$40.81 - $55.0 $451,276 - $608,190	-11,058 Reduced 4.68%	225,373 $11.8 Million

Q2 2024 Aug 13, 2024	BUY	$35.41 - $44.37 $1.04 Million - $1.31 Million	29,451 Added 14.23%	236,431 $9.71 Million
Q1 2024 May 15, 2024	SELL	$39.12 - $52.44 $115,716 - $155,117	-2,958 Reduced 1.41%	206,980 $8.97 Million
Q4 2023 Feb 14, 2024	SELL	$21.39 - $49.64 $2.72 Million - $6.32 Million	-127,326 Reduced 37.75%	209,938 $9.65 Million
Q3 2023 Nov 13, 2023	BUY	$15.81 - $27.8 $2.07 Million - $3.65 Million	131,229 Added 63.69%	337,264 $7.73 Million
Q1 2023 May 15, 2023	BUY	$16.88 - $34.24 $2.77 Million - $5.61 Million	163,838 Added 388.27%	206,035 $3.68 Million
Q4 2022 Feb 14, 2023	BUY	$22.21 - $30.25 $272,294 - $370,865	12,260 Added 40.95%	42,197 $1.23 Million
Q3 2022 Nov 14, 2022	SELL	$4.3 - $30.85 $107,009 - $767,733	-24,886 Reduced 45.39%	29,937 $0
Q2 2022 Aug 12, 2022	BUY	$3.12 - $12.25 $79,223 - $311,052	25,392 Added 86.28%	54,823 $227,000
Q4 2021 Feb 14, 2022	BUY	$8.62 - $13.9 $36,341 - $58,602	4,216 Added 16.72%	29,431 $293,000
Q2 2021 Aug 16, 2021	BUY	$18.52 - $22.55 $272,595 - $331,913	14,719 Added 140.23%	25,215 $493,000
Q1 2021 May 14, 2021	SELL	$20.25 - $39.49 $377,257 - $735,698	-18,630 Reduced 63.96%	10,496 $223,000
Q4 2020 Mar 01, 2021	SELL	$21.17 - $32.61 $60,080 - $92,547	-2,838 Reduced 8.88%	29,126 $865,000
Q3 2020 Nov 13, 2020	BUY	$18.13 - $30.61 $233,895 - $394,899	12,901 Added 67.68%	31,964 $692,000
Q2 2020 Aug 14, 2020	BUY	$14.41 - $25.35 $274,697 - $483,247	19,063 New	19,063 $425,000

Others Institutions Holding RYTM

# of Institutions

282

Shares Held

486M

Call Options Held

498K

Put Options Held

150K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $5.54B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Rhythm Pharmaceuticals, Inc. Transaction History